Systemic Treatment of Prostate Cancer

Paperback | March 5, 2010

EditorAlan Horwich

not yet rated|write a review
Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities formultiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay of endocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroidscan also cause remissions. In recent years effective and well-tolerated chemotherapy regimens have been developed and evaluated. Docetaxel has an established role, and a range of biologically-targeted agents are in development.The dominant pattern of metastatic spread is to the axial skeleton and most symptomatic care is directed to palliation of bone pain. The role of bisphosphonates remains controversial, but bone-directed isotopes such as Strontium-89 are effective.Part of the Oxford Oncology Library, this pocketbook summarises the up-to-date information on the use of systemic therapies in the management of prostate cancer (early stage, metastatic disease, and treatment of "biochemical" recurrence). With contributions from leading oncologists from both Europeand the USA, the book provides a practical guide to the range of endocrine and cytotoxic therapies currently available to clinicians, as well as to other palliative anticancer strategies, and will be valuable to all health professionals involved in the management of patients with prostatecancer.

Pricing and Purchase Info

$42.00

Ships within 1-3 weeks
Ships free on orders over $25

From the Publisher

Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities formultiple sequential therapeutic interventions. For ...

Alan Horwich is Professor of Oncology at the Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
Format:PaperbackDimensions:128 pages, 7.09 × 3.94 × 0.07 inPublished:March 5, 2010Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0199561427

ISBN - 13:9780199561421

Look for similar items by category:

Customer Reviews of Systemic Treatment of Prostate Cancer

Reviews

Extra Content

Table of Contents

1. Jonathan Waxman: Biological principles of hormone therapy2. Karim Fizazi: PSA as a marker of progression and response3. Mike D. Shelley and Malcolm D. Mason: Neoadjuvant and adjuvant hormone therapy for high-risk localized disease4. Stephen Freedland: Systemic treatment of recurrence after local therapies5. Ajjai S. Alva and Maha Hussain: First-line hormone therapy for metastatic prostate cancer6. Wolfgang Lilleby and Sophie Fossa: Second- and third-line hormone therapies7. Cora N. Sternberg and Fabio Calabro: Chemotherapy for metastatic prostate cancer8. Alan Horwich and David P. Dearnley: The role of bisphosphonates in prostate cancer9. Christopher C. Parker: Systemic isotope therapy of bone metastasis10. Shahneen Sandhu and Johann DeBono: The development of biologically targeted agents